$267 Million is the total value of Athyrium Capital Management, LP's 11 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Biora Inc.note 7.250% 12/0 | $62,761,000 | -4.2% | 103,500,000 | 0.0% | 23.51% | -14.7% | ||
| AMYT | Amryt Pharma PLCsponsored ads | $61,292,000 | -1.0% | 8,857,268 | 0.0% | 22.96% | -11.8% | |
| CMAX | Sell | CAREMAX INC | $31,673,000 | +94.4% | 4,467,219 | -0.4% | 11.86% | +73.1% |
| OSMT | Buy | RVL PHARMACEUTICALS PLC | $30,661,000 | +176.7% | 14,600,444 | +79.2% | 11.48% | +146.4% |
| Buy | Omeros Corpnote 5.250% 2/1 | $22,336,000 | +10.1% | 40,150,000 | +14.2% | 8.36% | -2.0% | |
| Omeros Corpnote 6.250%11/1 | $19,249,000 | +3.3% | 21,005,000 | 0.0% | 7.21% | -8.1% | ||
| PROG | Biora Inc. | $14,477,000 | -30.7% | 29,855,847 | 0.0% | 5.42% | -38.3% | |
| BridgeBio Pharma Inc.note 2.250% 2/0 | $8,718,000 | +3.9% | 20,000,000 | 0.0% | 3.26% | -7.5% | ||
| New | Paratek Pharmaceuticals Inc.note 4.750% 5/0 | $8,000,000 | – | 9,000,000 | +100.0% | 3.00% | – | |
| PBYI | PUMA BIOTECHNOLOGY INC | $4,247,000 | -16.9% | 1,792,114 | 0.0% | 1.59% | -25.9% | |
| REPH | Societal CDMO Inc. | $3,590,000 | +105.0% | 2,202,420 | 0.0% | 1.34% | +82.7% | |
| Exit | Paratek Pharmaceuticals Inc.note 4.750% 5/0 | $0 | – | -9,000,000 | -100.0% | -3.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Amryt Pharma PLC | 10 | Q1 2023 | 46.3% |
| Progenity Inc. | 9 | Q4 2022 | 69.2% |
| Progenity Inc. | 8 | Q3 2023 | 39.2% |
| RVL PHARMACEUTICALS PLC | 8 | Q3 2023 | 11.5% |
| Societal CDMO Inc. | 8 | Q4 2022 | 3.1% |
| Omeros Corp | 7 | Q3 2023 | 39.3% |
| CAREMAX INC | 7 | Q4 2022 | 27.5% |
| Omeros Corp | 7 | Q3 2023 | 9.9% |
| PUMA BIOTECHNOLOGY INC | 7 | Q3 2023 | 4.2% |
| AEGERION PHARMACEUTICALS INC | 6 | Q1 2019 | 88.7% |
View Athyrium Capital Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PROGENITY, INC. | August 27, 2021 | 4,211,977 | 2.7% |
View Athyrium Capital Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR/A | 2023-05-16 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Athyrium Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.